Diaz-Canel praised the company’s innovative capacity and emphasized that it has gained maturity and stability and is capable of facing current challenges. Therefore, he highlighted its entrepreneurial capacity and suggested exploring new markets within Asia and Eurasia.

In statements to Prensa Latina, Bai Xianhong, president of BPL, praised the contributions of Cuban scientists and experts, calling the venture the largest collaboration between the two nations in the biopharmaceutical industry.

He also highlighted the success of the first humanized monoclonal antibody, known as Nimotuzumab, which enabled the effective treatment of cancer in more than 300,000 Chinese patients.

The president also stated that cooperation with Cuba will continue in the coming years. The joint venture will improve monoclonal antibody production capacity and establish world-leading infusion lines based on mammalian cell culture.

Yanet Borrego, deputy director general and representative of the Cuban vice presidency of BPL, recalled that Nimotuzumab was registered in China for the treatment of head and neck cancer; it was previously used there to treat pancreatic and nasopharyngeal carcinoma.

He previously mentioned that the company is also working on the development of nine innovative products, also in cooperation with Cuba, which are currently in the research and development phase and should reach the market in approximately 10 years.

The country has three joint ventures developing innovative biopharmaceutical products, such as Nimotuzumab for the treatment of cancer, recombinant interferon alpha 2B for the treatment of hepatitis B, and Ateromixol (PPG) for reducing blood cholesterol levels.

ro/idm